Therapeutic Focus

Rodatristat Ethyl

Altavant’s lead candidate is rodatristat ethyl*, the prodrug of rodatristat, a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production. By lowering levels of serotonin in the circulation and in pulmonary tissues, rodatristat may represent a disease-modifying treatment for diseases characterized by pathological serotonin signaling. These diseases include pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) and sarcoidosis.

*For ease of reading, this website sometimes uses the name “rodatristat” to refer to the prodrug rodatristat ethyl in addition to the active moiety.


Compound Disease Phase
Rodatristat ethyl Pulmonary Arterial Hypertension (PAH) Phase 2
Idiopathic Pulmonary Fibrosis (IPF) Research
Sarcoidosis Research
ALTA-2530 Bronchiolitis Obliterans Syndrome IND Enabling
Next-Generation TPH Inhibitors Oral agents for multiple indications Research
Alternative routes of administration for multiple indications Research

CompoundDiseaseResearchIND EnablingPhase 1Phase 2Phase 3
Rodatristat Ethyl Pulmonary Arterial Hypertension (PAH)

Click to Learn More

Idiopathic Pulmonary Fibrosis (IPF)
ALTA-2530 Transplant-associated bronchiolitis obliterans syndrome
Chemical-induced bronchiolitis obliterans syndrome

* Partnered with BARDA / NIAID

Next-Generation TPH Inhibitors Oral agents for multiple indications
Alternative routes of administration of multiple indications